James Howard Tonsgard to United States
This is a "connection" page, showing publications James Howard Tonsgard has written about United States.
Connection Strength
0.020
-
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. J Clin Oncol. 2021 03 01; 39(7):797-806.
Score: 0.020